Clinical and Translational Evaluation of a SAMe-5-HTP-Hypericum Compound Nutritional Supplement for Emotional Support and Joint Care
Frontiers in Science and Engineering · 22.04.2026 · 6 (4) · 174-180
DOI: 10.54691/n699qh86 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Science and Engineering, online erschienen am 22.04.2026. Verfasst von Jabar Yassine und 2 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
We evaluated a disclosed SAMe-5-HTP-Hypericum compound nutritional supplement developed for dual-domain emotional support and joint care, and we aligned the disclosed formulation data with published human clinical evidence for the principal active ingredients. The formulation combines S-adenosyl-L-methionine (SAMe), 5-hydroxytryptophan (5-HTP), and St. John's wort extract with sodium chondroitin sulfate, sodium hyaluronate, vitamin B6, vitamin E, and phosphatidylserine. We selected the upper-limit formulation as the lead candidate because it showed the best disclosed performance across both emotional-support and joint-care models. In the forced-swimming model, the lead formulation reduced immobility time to 108.7 ± 11.2 s versus 142.8 ± 14.6 s for the comparator formulation without the joint-care synergists. In the rat osteoarthritis model, it increased cartilage matrix synthesis to 1089 ± 91 cpm/mg and synovial fluid viscosity to 11.2 ± 1.0 mPa·s, outperforming the comparator values of 721 ± 68 cpm/mg and 7.2 ± 0.7 mPa·s. Published human evidence showed that SAMe monotherapy was superior to placebo for depressive symptoms in a 2024 meta-analysis (23 trials, N = 2183; SMD = -0.58), St. John's wort was superior to placebo for mild-to-moderate depression and not significantly different from antidepressants in effectiveness while showing fewer adverse events, 5-HTP showed a pooled remission rate of 0.65 but with marked methodological weakness, and chondroitin provided a small-to-moderate short-term benefit in osteoarthritis. Taken together, these findings support a clinically plausible and mechanistically coherent dual-domain supplement architecture. Direct randomized clinical trials of the finished composition remain necessary before therapeutic superiority claims can be finalized.
Zitieren
APA
Yassine, J., Semenza, G. L., & Morett, V. (2026). Clinical and Translational Evaluation of a SAMe-5-HTP-Hypericum Compound Nutritional Supplement for Emotional Support and Joint Care. Frontiers in Science and Engineering, 6(4), 174-180. https://doi.org/10.54691/n699qh86
Vancouver
Yassine J, Semenza GL, Morett V. Clinical and Translational Evaluation of a SAMe-5-HTP-Hypericum Compound Nutritional Supplement for Emotional Support and Joint Care. Frontiers in Science and Engineering. 2026;6(4):174-180. doi:10.54691/n699qh86
BibTeX
@article{Yassine2026,
author = {Yassine, Jabar and Semenza, Gregg L. and Morett, Vincenzo},
title = {Clinical and Translational Evaluation of a SAMe-5-HTP-Hypericum Compound Nutritional Supplement for Emotional Support and Joint Care},
journal = {Frontiers in Science and Engineering},
year = {2026},
volume = {6},
number = {4},
pages = {174--180},
doi = {10.54691/n699qh86}
}
EUVIMED